Gain Therapeutics completes MAD dosing for GT-02287 Phase 1; no SAEs, on track for Q4 2024 patient trial

Gain Therapeutics, Inc.

Completed dosing in MAD part of Phase 1 study of GT-02287 for Parkinson's disease; no discontinuations or serious adverse events.
GT-02287 well tolerated up to highest planned dose; 90% of adverse events mild, 10% moderate, no Grade 3+ events.
Topline data expected mid-August after database lock; full safety and PK data to be presented at future congress.
On track to initiate clinical trial in Parkinson's disease patients by Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.